Jiang et al., 2021 [8] developed an immune-related risk model centered on FOXP3 expression, while Luo et al., 2020 [29] demonstrated the utility of CpG methylation patterns in forecasting recurrence and guiding immunotherapy responses in non-small cell lung cancer. The gene discussed is FOXP3; the disease is non-small cell lung carcinoma.